Early patient data suggests that FlowOx™ may have a role in Multiple Sclerosis (MS) symptoms management
Preliminary results from an exploratory pilot investigation carried out by Neuro-SysMed, Norway’s leading center of excellence in Neurological research, were presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)1.
Based on the promising results from the pilot study at Haukeland, Otivio and NeuroSysmed decided to initiate a larger randomized controlled trial in Scandinavia.
IN THE PRESS
First RCT to show improved walking capacity
First multi-centre randomized controlled trial using FlowOx™, published in Journal of Vascular Surgery, shows improved walking capacity for patients with intermittent claudication, also known as “windows shopper’s disease”.
Read more here!
Is FlowOx™ for me?
Without FlowOx™ I would have lost my other leg as well and I am not sure I would have been here today. That is what FlowOx™ has done for me..
Listen to Stine’s and Hans Thomas’ stories
Stine’s own story
First FlowOx™ patient, Hans Thomas
FlowOx™ by Otivio
Otivio AS is a Norwegian medtech company based in Oslo. FlowOx™ is a non-invasive medical device for home treatment addressing insufficient blood flow to the limbs associated with peripheral arterial disease, diabetes and other arterial blood flow deficiencies. FlowOx™ is documented to reduce or eliminate these outcomes which represent a big impact on Quality of Life and health care costs. FlowOx™ is CE marked (CE2460) and available in various countries.
GET IN TOUCH